mbf-015
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2021 (NCT06049147)
Timeline
Indications
Mechanism of action
- Histone deacetylaseINHIBITOR
HDAC1 inhibitor
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06469853 | Phase 2 | Feb 1, 2024 | Medibiofarma S.L. |
| NCT06049147 | Phase 1 | Jul 7, 2021 | Medibiofarma S.L., University of Barcelona |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medibiofarma S.L. | For profit | 2 | 2 | 2 | 2021 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1